Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while protecting healthy tissue and reducing side effects. The new approach utilizes a single molecule designed to bind two proteins with differing affinities in an effort to optimize specific tumor localization — prostate-specific membrane antigen (PSMA) and human serum albumin — thereby enhancing tumor localization for targeted alpha radionuclide therapy. The study is presented in the featured basic article of the September issue of The Journal of Nuclear Medicine.

September 13, 2017 — Since announcing the integration of CareSelect Imaging with Epic's enterprise electronic health ...

Nuance Communications Inc. announced that Citizens Medical Center, a critical access hospital in rural Kansas, has completed a hospital-wide deployment of Nuance solutions to reduce transcription costs and improve physician satisfaction, productivity and efficiency. The implementation includes Dragon Medical One, eScription RH, PowerMic Mobile and the PowerShare Network.

Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from Sept. 11 – 14, 2017, applying advanced technologies and deep clinical insights to address peripheral vascular needs. With the addition of its recent acquisition, Spectranetics, Philips will for the first time highlight its expanded portfolio of interventional X-ray systems, advanced catheters for measurement and therapy, clinical informatics and services, including its Philips Azurion image-guided therapy platform, intravascular ultrasound (IVUS), Phoenix atherectomy system and Spectranetics' Stellarex drug-coated balloon.